Sunshine Biopharma Inc. reported a net loss of $4.03 million for the nine months ended September 30, 2026, compared to a loss of $3.83 million in the prior year period. While revenues decreased slightly to $26.79 million, the company significantly strengthened its cash position to $14.62 million through public offerings and warrant exercises.
The majority shareholder and CEO, Dr. Steve N. Slilaty, approved by written consent several matters related to a public offering that closed on October 9, 2026. These approvals include the issuance of common stock in excess of 20% of outstanding shares at a discount and adjustments to the exercise price and share count of Series D Warrants.
Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.
Sunshine Biopharma's majority shareholder, CEO Dr. Steve N. Slilaty, has approved a written consent authorizing the board to effect a reverse stock split at a ratio of up to 1-for-20. The board retains discretion over the final ratio and the timing of the split, which will become effective 20 days after a definitive information statement is mailed to stockholders.
Sunshine Biopharma announced a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. This adjustment was triggered by recent sales of common stock under the company's existing at-the-market (ATM) offering program. The price remains subject to further potential adjustments based on the terms of the warrants.